Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2010
04/21/2010CN101695481A Mitiglinide calcium dispersible tablet and preparation method thereof
04/21/2010CN101695480A Olopatadine hydrochloride dispersible tablets, preparation method thereof and quality control method thereof
04/21/2010CN101695479A Instant pirarubicin freeze-dried powder injection and preparation method thereof
04/21/2010CN101695478A Tamsulosin hydrochloride sustained-release pellets and preparation method thereof
04/21/2010CN101695476A Method for preparing medical nanoparticles
04/21/2010CN101695475A Ozagrel sodium injection and preparation method thereof
04/21/2010CN101695474A Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
04/21/2010CN101390848B Medicine composition azithromycin enteric-coated capsules
04/21/2010CN101357132B Composition for treating hyperlipemia
04/21/2010CN101327208B Use of Carthamus tinctorius yellow colour in preparing medicament for treating and/or preventing lung damnification
04/21/2010CN101249085B Bilobalide A, B compound injection and preparation method and application thereof
04/21/2010CN101230003B Preparation method of salvia miltiorrhiza tanshinoate A
04/21/2010CN101181290B Pharmaceutical composition and preparation method thereof
04/21/2010CN101167719B Gallo catechin and gallate microcapsule granule and preparation technique thereof
04/21/2010CN101167710B Chloromycetin eyedrops with long quality guaranteed period and preparation method thereof
04/21/2010CN101156865B Antineoplastic new usage of cardiac glycoside compound in antiar
04/21/2010CN101156847B Usage of purplish plastocyanin as insulin sensitization agent
04/21/2010CN101152378B Externally used traditional Chinese medicine preparation for diminishing the inflammation and reducing the pain
04/21/2010CN101129358B Moguisteine sustained-release tablet and method of preparing the same
04/21/2010CN101085076B Chinese and Western medicine united sustained-release injection for preventing and controlling coccidiosis of rabbit and its preparation method
04/21/2010CN101074259B Saponin compound, its production and use
04/21/2010CN101041652B Separating purified new bisflavone compound from dragon's blood and preparation method thereof
04/21/2010CN101037465B Saponins and preparation method and application
04/21/2010CN101036637B Application of salvia miltiorrhiza bge I sodium sulfonate in the preparation of medicine
04/21/2010CN101018846B Method for producing unsaturated fatty acid concentrate
04/20/2010USRE41253 Antineoplastic combinations
04/20/2010USRE41252 Peptidyl prodrugs and linkers and stabilizers useful therefor
04/20/2010US7700792 Highly active lysophosphatidic acid and method of screening therewith
04/20/2010US7700782 Compound containing benzothiazol-2-one ring; adrenergic receptor; adult respiratory distress syndrome, bronchitis, asthma, chronic obstructive pulmonary disease, antiinflammatory agents
04/20/2010US7700778 Acylated piperidine derivatives as melanocortin-4 receptor agonists
04/20/2010US7700775 Drug delivery
04/20/2010US7700772 Amino heterocyclic modulators of chemokine receptor activity
04/20/2010US7700771 antiinflammatory agents; antiarthritic agents
04/20/2010US7700770 recrystallizing from a polar aprotic solvent (dimethylsulfoxide, dimethylformamide, dimethylacetamide, or N-methylpyrrolidinone) and a cosolvent (acetonitrile, ethanol, methylethyl ketone, isopropyl alcohol, or 1-propanol); myelodysplastic syndrome
04/20/2010US7700768 such as 7-Methylsulfanyl-5-phenyl-1-(1-phenylethyl)-3,4-dihydro-1H -pyrimido[4,5-d]pyrimidin-2-one; p38 map kinase inhibitors
04/20/2010US7700765 DNA minor groove binding compounds
04/20/2010US7700763 3-triazolyl-galactoside inhibitors of galectins
04/20/2010US7700761 3-deoxypentopyranosyl nucleic acid, its production and its use
04/20/2010US7700758 Preparing library of heterogenous small interfering RNA sequences (HSIRNA) for use in gene expression inhibition and mammalian therapeutics; gene therapy
04/20/2010US7700749 Nucleic acid and corresponding protein entitled 205P1B5 useful in treatment and detection of cancer
04/20/2010US7700747 Crosslinked polysaccharide sponge
04/20/2010US7700746 Matrix material comprising agarose linked di-and trisaccharides for use in blood, food, water and viruses filtering; protein separation
04/20/2010US7700722 Polyoxyethylene glycol-modified tumor necrosis factor for higher concentrations, decreased viscosity, and improved stability; for treatment of inflammation
04/20/2010US7700715 Kit for use in the diagnosis and treatment of cancer
04/20/2010US7700658 Administering 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2- tetrafluoroethoxy)phenyl]-methyl]amino]- 1,1,1-trifluoro-2-propanol(ylgucpd25); anticholesterol agents to increase the level of high density lipoproteins; atherosclerosis; coronary artery; strokes, cardiovasculardiseases; dyslipidemia
04/20/2010US7700657 Vitamin D analogs
04/20/2010US7700656 Parasisicides; anthelmintics; veterinary medicine
04/20/2010US7700655 Antiallergic agents
04/20/2010US7700654 isolating a substance having antiandrogenic activity from the bark of the African plum tree P. africana, and synthesising structural variants of these substances; even able to inhibit the growth of prostate cancer cells that do not respond to treatment with hydroxyflutamide
04/20/2010US7700653 Hypotensive agents; cardiovascular disorders
04/20/2010US7700652 Treating urinary incontinence using prodrugs of GABA analogs
04/20/2010US7700651 Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
04/20/2010US7700650 Lipoxin analogs and method for the treatment of periodontal disease
04/20/2010US7700649 Such as 1,2-Ethanediamine-trans-dihydroxo(dihydrogen pyrophosphato)platinum(IV)
04/20/2010US7700647 dehydrating fluorinated bis(phthalic acid by using an aliphatic carboxylic anhydride in an organic solvent, crystallization in poor solvent, reacting intermediate with a diamine to form polyamic acid and polyamide; Has less coloration and higher solubility
04/20/2010US7700646 Compounds for use in the treatment of infection
04/20/2010US7700645 Comprising the ethanolate solvate of Prezista" aka darunavir ethanolate; improved pharmacokinetics;stability; bioavailability; purity; industrial scale; viricides
04/20/2010US7700644 Isoflavonoid dimers
04/20/2010US7700643 for use in charge injection layer, planarizing layer, antistatic film or conducting substrate or pattern for electronic applications or flat panel displays; semiconductors; electrooptics
04/20/2010US7700642 Reacting 3-(4-fluorophenyl)-1-isopropyl-1H-indole, 3,3-dimethoxypropionate, acetic acid and phosphorus oxychloride obtaining trans-3-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]acrylate
04/20/2010US7700641 Spiro-oxindole compounds and their uses as therapeutic agents
04/20/2010US7700640 Process for making phenoxy benzamide compounds
04/20/2010US7700638 Such as 7-(3-Chlorophenyl)-1-phenyl-5-trifluoromethylbenzimidazole; antianxiety agents; side effect reduction
04/20/2010US7700637 Organic compounds
04/20/2010US7700636 Protein kinase inhibitors; antiproliferative agents; anticancer agents;antiinflammatory agents; metabolism disorders; antidiabetic agents
04/20/2010US7700635 Neuroprotectants; treatment of neuropathies resulting from chemtherapeutic agents used in the treatment of HIV and proliferative disease such as cancer and treatment of inflammatory diseases; neurodegenerative diseases; enzyme inhibitorsfor seine/threonine kinases, phosphatases; Alzheimer's
04/20/2010US7700633 5-(3,6-Dihydroxynaphthalen-2-yl)-1,1-dioxo-1,2,5-thiadiazolidin-3-one; inhibitors of protein tyrosine phosphatases; in combination with an anti-diabetic agents, a hypolipidemic agent, an anti-obesity agent or an anti-hypertensive agent
04/20/2010US7700632 3-(3-Chloro-biphenyl-4-yloxymethyl)-benzoic acid; antidiabetic; type 2 diabetes, insulin resistance, impaired glucose tolerance, obesity
04/20/2010US7700631 Use of pyridine N-oxide analogs at doses which do not induce emesis
04/20/2010US7700630 3-Quinolin-2-ylmethylene-3,4,5,6-terahydro[2,3']bipyridinyl; for therapy and prophylaxis of psychotic diseases, neurodegenerative diseases involving a dysfunction of the cholinergic system
04/20/2010US7700629 Use of a non-racemic mixture of bupivacaine enantiomers, for improving the anesthesia profile
04/20/2010US7700628 Aromatic ether derivatives useful as thrombin inhibitors
04/20/2010US7700627 5-{(R)-1-[4-(1-Hydroxyhexyl)phenyl]-6-oxopiperidin-2-ylmethoxymethyl}-thiophene-2-carboxylic acid
04/20/2010US7700626 Such as alvimopan and active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits; lyophilization; vacuum drying; storage stability
04/20/2010US7700625 Hydroxybenzamide derivatives and their use as inhibitors of Hsp90
04/20/2010US7700624 To treat inflammatory diseases, immune diseases and cancer; 4-{[(1R3S)-3-isopropyl-3-({4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)cyclopentyl]amino}-1-(5-pyrimidin-2-ylpyridin-2-yl)cyclohexanol; side effect reduction; improved long term safety profile; oral administration; half life
04/20/2010US7700623 Arylamidine derivative, salt thereof, and antifungal containing these
04/20/2010US7700622 Antiinflammatory agents; autoimmune disease; bone disorders; viricides; antiproliferative agents; antiarthritic agents
04/20/2010US7700620 C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
04/20/2010US7700618 2-{[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)-1H-benzimidazol-5-yl]sulfonyl}-N,N,2-trimethylpropanamide; condition mediated by CB2 receptors; less toxicity, good absorption, distribution, solubility, metabolic stability, less protein binding affinity other than CB2 receptor, less drug-drug interaction
04/20/2010US7700617 Salt of naphthyridine carboxylic acid derivative
04/20/2010US7700616 Compounds and amyloid probes thereof for therapeutic and imaging uses
04/20/2010US7700615 comprises 4-methyl-3-nitro-benzoic acid as inhibitor and 1,3-bis(2-chloroethyl)-1-nitrosourea as chemotherapeutic agent; for treatment of breast cancer and melanomas
04/20/2010US7700613 Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms
04/20/2010US7700612 improved bioavailability, reduced toxicity; anticancer agents
04/20/2010US7700611 Synthesis and crystalline forms of NPY5 antagonist
04/20/2010US7700610 Use of tyrosine kinase inhibitors for treating allergic diseases
04/20/2010US7700609 antiproliferative agents; antiinflammatory agents; neurodegenerative agents; autoimmune disease; viricides
04/20/2010US7700608 Quinazoline derivatives and their use in the treatment of thrombocythemia
04/20/2010US7700607 Substituted pyridone compounds and methods of use
04/20/2010US7700606 Such as 8-[3-(2-Fluoropyridin-3-yl)phenyl]-8-pyridin-4-yl-2,3,4,8-tetrahydroimidazo[1,5-a]pyrimidin-6-amine; amyloid disorders, Alzheimer's disease, Down's syndrome
04/20/2010US7700605 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors
04/20/2010US7700604 (5S)-5-methyl-5-({[6-[2-(trifluoromethyl)pyrimidin-5-yl]-3,4-dihydroisoquinolin-2(1H)-yl]sulfonyl}methyl)imidazolidine-2,4-dione; asthma, rhinitis, chronic obstructive pulmonary diseases (COPD), arthritis (such as rheumatoid arthritis and osteoarthritis), atherosclerosis, cancer
04/20/2010US7700602 And beta-amyloid formation; Alzheimer's Disease; 2-amino-5-(4-fluoro-3-pyrimidin-5-ylphenyl)-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
04/20/2010US7700601 Substituted indazoles of formula 1.0 that are kinase inhibitors
04/20/2010US7700600 Using vanoxerine type medicant; blocking calcium channel current
04/20/2010US7700599 G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient
04/20/2010US7700598 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
04/20/2010US7700597 For treating diseases or conditions mediated by cannabinoid receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (smoking cessation), gastrointestinal disorders, and cardiovascular conditions
04/20/2010US7700596 such as 3-(6-Methoxy-naphthalen-2-yl)-9-methyl-3,9-diaza-bicyclo[3.3.1]nonane
1 ... 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 ... 7860